-- Novartis Shifts Clinical Trials to Emerging Markets, HB Reports
-- B y   E v a   v o n   S c h a p e r
-- 2012-09-12T05:59:45Z
-- http://www.bloomberg.com/news/2012-09-12/novartis-shifts-clinical-trials-to-emerging-markets-hb-reports.html
Novartis AG (NOVN)  is shifting more of its
clinical trials to emerging market regions such as Asia-Pacific,
the Middle East and Africa,  Handelsblatt  reported, citing
Novartis information.  The number of clinical trials rose to 44 percent of all of
Novartis trials, not including trials of cancer drugs, the
newspaper reported.  To contact the reporter on this story:
Eva von Schaper in Munich at 
 evonschaper@bloomberg.net   To contact the editor responsible for this story:
Phil Serafino at 
 pserafino@bloomberg.net  